Biondvax Pharmaceuticals Ltd - ADR

NASDAQ:BVXV   3:59:53 PM EDT
1.24
-0.03 (-2.36%)
Products, Strategic Combinations

BiondVax Signs Definitive Collaboration Agreement For Development Of Pipeline Of Innovative Nanosized Antibody Therapies

Published: 03/24/2022 11:17 GMT
Biondvax Pharmaceuticals Ltd - ADR (BVXV) - Biondvax Signs Definitive Collaboration Agreement for the Development of a Pipeline of Innovative Nanosized Antibody (nanoab) Therapies.
Biondvax Pharmaceuticals Ltd - New Nanoab Pipeline Development Already Initiated With Preclinical Results Anticipated 2023.
Biondvax Pharmaceuticals Ltd - Anticipates Conducting a Preclinical Proof of Concept Study of Inhaled Covid-19 Nanoabs in 2022.